In the next few decades, the world population will flourish. As the population grows rapidly and people all over the world use more and more resources, all industries must consider their environmental impact. 133081-25-1, name is 6-(2-(tert-Butoxycarbonyl)hydrazinyl)nicotinic acid, the common compound, a new synthetic route is introduced below. Recommanded Product: 6-(2-(tert-Butoxycarbonyl)hydrazinyl)nicotinic acid
4. Synthesis of ((3aR, 4R, 6R, 6aR)-6-(7-allyl-2 -amino-6, 8-dioxo-], 6,7,8-tetrahydropurin-9-yl)-2, 2-dimethyl-tetrahydrofuro[3, 4-dill, 3]dioxol-4-ylfrnethyl 6-(2- (tert-butoxycarbonyl)hydrazinyl)nicotinate To a suspension of 6-(2-(tert-butoxycarbonyl)hydrazinyl)nicotinic acid (668 mg,2.63 mmol) in toluene (10 mL, anhydrous) was added 2,4,6-trichlorobenzoyl chloride(959 mg, 3.95 mmol) and DIPEA(679 mg, 5.62 mmol). The suspension was stirred for10 mm and then a suspension of 7-allyl-2-amino-9-((3aR,4R,6R,6aR)-6-(hydroxymethyl)-2,2-dimethyl-tetrahydrofuro[3 ,4-dj [1 ,3]dioxol-4-yl)- lil-purine6,8(711,9H)-dione (500 mg,1.32 mmol) and DMAP (321 mg, 2.63 mmol) in toluene (10 mL, anhydrous) was added. The suspension was stirred for 15 hrs then quenched with brine. The aqueous phase was extracted with EtOAc (20 mL*3). The organic phase was combined, dried over Na2504, filtered and concentrated. The residue was purified byreverse phase biotage to give a white solid product (390 mg, 48%).
The synthetic route of 133081-25-1 has been constantly updated, and we look forward to future research findings.
Reference:
Patent; ASCEND BIOPHARMACEUTICALS PTY LTD; PIETERSZ, Geoffrey, Alan; WO2013/67597; (2013); A1;,
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem